[Effect of combined use of CR1505 with UFT for the tumor growth of the subcutaneously transplanted pancreatic cancer in the Syrian golden hamsters].
We studied on the effect of combined use of CR1505 with UFT for the subcutaneously transplanted pancreatic cancer induced by BOP (N-nitrosobis (2-oxopropyl) amine) in the Syrian golden hamsters. The tumor growth in the group treated with both CR1505 and UFT was significantly inhibited compared with that in the group treated with only CR1505 or UFT. Labelling index judged by BrdU immunohistochemistry in the group with the combined use was significantly lower than that in the group with the single use. The differences of the body weights and blood analysis were not obscured in the both groups. Moreover, the concentrations of 5-FU and FT207 in tumors were not different between them. These results suggest that a new therapy of the combined use with CR1505 and UFT for the pancreatic cancer should be effective.
First Department of Surgery, Kobe University School of Medicine.
M
M
Tomioka
N
N
Miyazaki
M
M
Yamamoto
Y
Y
Saito
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002766:Cholecystokinin / Q000037:antagonists & inhibitors; D006224:Cricetinae; D008647:Mesocricetus; D009368:Neoplasm Transplantation; D009602:Nitrosamines; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D011377:Proglumide / Q000008:administration & dosage / Q000031:analogs & derivatives; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D009602:Nitrosamines; D005641:Tegafur; D014498:Uracil; C013622:nitrosobis(2-oxopropyl)amine; C053737:loxiglumide; D002766:Cholecystokinin; D011377:Proglumide